Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an alpha-ENaC (SCNN1A) gene. The alpha-ENaC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an alpha-ENaC gene. Pharmaceutical compositions that include one or more alpha-ENaC RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described alpha-ENaC RNAi agents to epithelial cells, such as pulmonary epithelial cells,in vivo, provides for inhibition of alpha-ENaC gene expression and a reduction in ENaC activity, which can provide a therapeutic benefit to subjects, including human subjects.本發明描述用於抑制α-ENaC (SCNN1A)基因之RNAi試劑、包括RNAi試劑之組合物及方法。本文中所揭示之α-ENaC RNAi試劑及RNAi試劑結合物抑制α-ENaC基因之表現。本發明亦描述包括一或多種α-ENaC RNAi試劑與視情況存在之一或多種額外治療劑的醫藥組合物。在活體內將所描述之α-ENaC RNAi試劑遞送至諸如肺上皮細胞之上皮細胞中提供α-ENaC基因表現抑制及ENaC活性降低，其可以為包括人類個體之個體提供治療效益。
